iCAD to Present at the Eighth Annual Needham and Company Biotechnology and Medical Technology Conference
Tuesday, 02 June 2009 07:19 | 
| Company News - iCAD, Inc. |
iCAD, Inc. announced that Ken Ferry, Chief Executive Officer, and Darlene Deptula-Hicks, Executive Vice President and Chief Financial Officer of iCAD, will be presenting a corporate update at the Eighth Annual Needham and Company Biotechnology and Medical Technology Conference.
iCAD, Inc. (Nasdaq: ICAD), an industry-leading provider of Computer-Aided Detection (CAD) solutions, announced that Ken Ferry, Chief Executive Officer, and Darlene Deptula-Hicks, Executive Vice President and Chief Financial Officer of iCAD, will be presenting a corporate update at the Eighth Annual Needham and Company Biotechnology and Medical Technology Conference on Wednesday, June 10, 2009 at 11:30 a.m., (Eastern Daylight Time) at The New York Palace Hotel in New York City. The presentation will be followed by a breakout session scheduled to take place at 1:00 p.m.
Management will also be available for one-on-one meetings with investors participating in the Needham and Company Conference. For those who would like to schedule an appointment with iCAD management, please contact Anne Marie Fields, Lippert/Heilshorn & Associates, Inc., at 212-838-3777 or at This e-mail address is being protected from spambots. You need JavaScript enabled to view it or contact your Needham and Company representative.
An audio presentation will be webcast live at http://www.wsw.com/webcast/needham31/icad/ and at www.icadmed.com on the “Investors” section of the company’s web site.
About iCAD, Inc.
iCAD, Inc. is an industry-leading provider of advanced image analysis and workflow solutions that enable healthcare professionals to better serve patients by identifying pathologies and pinpointing cancer earlier. iCAD offers a comprehensive range of high-performance, upgradeable Computer-Aided Detection (CAD) systems and workflow solutions for mammography (film-based, digital radiography (DR) and computed radiography (CR)), Magnetic Resonance Imaging (MRI), and Computed Tomography (CT). Since receiving FDA approval for the Company’s first breast cancer detection product in 2002, over 3,100 iCAD systems have been placed in healthcare practices worldwide. iCAD’s solutions aid in the early detection of the most prevalent cancers including breast, prostate and in the future, colon and lung cancer. For more information, call (877) iCADnow or visit www.icadmed.com.
Source: iCAD, Inc.
iCAD, Inc. (Nasdaq: ICAD), an industry-leading provider of Computer-Aided Detection (CAD) solutions, announced that Ken Ferry, Chief Executive Officer, and Darlene Deptula-Hicks, Executive Vice President and Chief Financial Officer of iCAD, will be presenting a corporate update at the Eighth Annual Needham and Company Biotechnology and Medical Technology Conference on Wednesday, June 10, 2009 at 11:30 a.m., (Eastern Daylight Time) at The New York Palace Hotel in New York City. The presentation will be followed by a breakout session scheduled to take place at 1:00 p.m.
Management will also be available for one-on-one meetings with investors participating in the Needham and Company Conference. For those who would like to schedule an appointment with iCAD management, please contact Anne Marie Fields, Lippert/Heilshorn & Associates, Inc., at 212-838-3777 or at This e-mail address is being protected from spambots. You need JavaScript enabled to view it or contact your Needham and Company representative.
An audio presentation will be webcast live at http://www.wsw.com/webcast/needham31/icad/ and at www.icadmed.com on the “Investors” section of the company’s web site.
About iCAD, Inc.
iCAD, Inc. is an industry-leading provider of advanced image analysis and workflow solutions that enable healthcare professionals to better serve patients by identifying pathologies and pinpointing cancer earlier. iCAD offers a comprehensive range of high-performance, upgradeable Computer-Aided Detection (CAD) systems and workflow solutions for mammography (film-based, digital radiography (DR) and computed radiography (CR)), Magnetic Resonance Imaging (MRI), and Computed Tomography (CT). Since receiving FDA approval for the Company’s first breast cancer detection product in 2002, over 3,100 iCAD systems have been placed in healthcare practices worldwide. iCAD’s solutions aid in the early detection of the most prevalent cancers including breast, prostate and in the future, colon and lung cancer. For more information, call (877) iCADnow or visit www.icadmed.com.
Source: iCAD, Inc.
Related Articles/Posts
Tags: iCAD - Medical Technology Conference - digital radiography - computed radiography - Computed Tomography - DR - CR - CT - product review - education - IT Management - Informatics
Set as favorite
Bookmark
Email this
Hits: 337
Trackback(0)
TrackBack URI for this entry
Comments (0)
Subscribe to this comment's feed
Write comment
